MD3811927T2 - O formă de dozaj parenterală stabilă de acetat de cetrorelix - Google Patents

O formă de dozaj parenterală stabilă de acetat de cetrorelix

Info

Publication number
MD3811927T2
MD3811927T2 MDE20220046T MDE20220046T MD3811927T2 MD 3811927 T2 MD3811927 T2 MD 3811927T2 MD E20220046 T MDE20220046 T MD E20220046T MD E20220046 T MDE20220046 T MD E20220046T MD 3811927 T2 MD3811927 T2 MD 3811927T2
Authority
MD
Moldova
Prior art keywords
dosage form
parenteral dosage
cetrorelix acetate
stable
inject
Prior art date
Application number
MDE20220046T
Other languages
English (en)
Inventor
Jaydip Joshi
Rakesh Thummar
Sudeep Agrawal
Subhas Balaram Bhowmick
Arunkumar Yadav
Rajamannar Thennati
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69784288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3811927(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MD3811927T2 publication Critical patent/MD3811927T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/16Injection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Prezenta invenţie se referă la o formă de dozare parenterală stabilă cu o soluţie apoasă stabilă sterilă de acetat de Cetrorelix, gata de injectat. Invenţia se referă, de asemenea, la un dispozitiv de injectare pre-umplut cu soluţie apoasă stabilă sterilă gata de injectat de acetat de Cetrorelix. Prezenta invenţie se referă la o utilizare a unei forme de dozare parenterală care cuprinde o soluţie apoasă sterilă, stabilă, gata de injectat, de acetat de Cetrorelix pentru inhibarea creşterilor premature ale hormonului luteinizant la femeile supuse stimulării ovariane controlate.
MDE20220046T 2019-10-24 2020-03-10 O formă de dozaj parenterală stabilă de acetat de cetrorelix MD3811927T2 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921043355 2019-10-24

Publications (1)

Publication Number Publication Date
MD3811927T2 true MD3811927T2 (ro) 2022-03-31

Family

ID=69784288

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20220046T MD3811927T2 (ro) 2019-10-24 2020-03-10 O formă de dozaj parenterală stabilă de acetat de cetrorelix

Country Status (28)

Country Link
US (2) US20210121517A1 (ro)
EP (2) EP3811927B8 (ro)
JP (1) JP2023501902A (ro)
KR (1) KR20220114533A (ro)
CN (1) CN114599384A (ro)
AR (1) AR120290A1 (ro)
AU (1) AU2020369236A1 (ro)
BR (1) BR112022007746A2 (ro)
CA (1) CA3155348A1 (ro)
CL (1) CL2022001021A1 (ro)
CO (1) CO2022006820A2 (ro)
DK (1) DK3811927T3 (ro)
ES (1) ES2902784T3 (ro)
HR (1) HRP20211890T1 (ro)
HU (1) HUE058963T2 (ro)
IL (1) IL293908A (ro)
JO (1) JOP20220094A1 (ro)
LT (1) LT3811927T (ro)
MA (2) MA55417B1 (ro)
MD (1) MD3811927T2 (ro)
MX (1) MX2022004859A (ro)
PL (1) PL3811927T3 (ro)
PT (1) PT3811927T (ro)
RS (1) RS62754B1 (ro)
SI (1) SI3811927T1 (ro)
TW (1) TW202128210A (ro)
WO (1) WO2021079339A1 (ro)
ZA (1) ZA202204282B (ro)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3811927T2 (ro) 2019-10-24 2022-03-31 Sun Pharmaceutical Ind Ltd O formă de dozaj parenterală stabilă de acetat de cetrorelix
WO2022269572A1 (en) 2021-06-25 2022-12-29 Extrovis Ag Pharmaceutical compositions
CN115184507A (zh) * 2022-07-27 2022-10-14 南京锐志生物医药有限公司 一种多肽中n,n-二异丙基碳二亚胺和哌啶的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10024451A1 (de) 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
DE10157628A1 (de) 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
AU2003269747A1 (en) 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited A stable aqueous composition of a peptide
EP2648755A1 (en) 2010-12-06 2013-10-16 Astron Research Limited A stable ready-to-use cetrorelix injection
US20130288968A1 (en) 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
US20130303453A1 (en) 2012-05-09 2013-11-14 Sun Pharmaceutical Industries Ltd. Octreotide injection
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
WO2018211526A1 (en) 2017-05-15 2018-11-22 Sun Pharmaceutical Industries Limited Octreotide injection
MD3811927T2 (ro) 2019-10-24 2022-03-31 Sun Pharmaceutical Ind Ltd O formă de dozaj parenterală stabilă de acetat de cetrorelix

Also Published As

Publication number Publication date
AU2020369236A1 (en) 2022-05-19
MA54713A (fr) 2021-11-17
DK3811927T3 (da) 2021-12-13
HRP20211890T1 (hr) 2022-03-04
EP3811927A1 (en) 2021-04-28
EP3811927B8 (en) 2022-02-23
EP3811927B1 (en) 2021-11-17
PT3811927T (pt) 2021-12-14
EP3908259A1 (en) 2021-11-17
BR112022007746A2 (pt) 2022-07-05
ES2902784T3 (es) 2022-03-29
US20220153802A1 (en) 2022-05-19
MA55417B1 (fr) 2022-02-28
RS62754B1 (sr) 2022-01-31
MX2022004859A (es) 2022-05-19
PL3811927T3 (pl) 2022-02-07
SI3811927T1 (sl) 2022-03-31
CO2022006820A2 (es) 2022-06-10
CN114599384A (zh) 2022-06-07
JOP20220094A1 (ar) 2023-01-30
IL293908A (en) 2022-08-01
ZA202204282B (en) 2024-01-31
HUE058963T2 (hu) 2022-10-28
KR20220114533A (ko) 2022-08-17
LT3811927T (lt) 2022-01-10
MA55417A (fr) 2021-04-28
CL2022001021A1 (es) 2023-02-03
CA3155348A1 (en) 2021-04-29
US20210121517A1 (en) 2021-04-29
WO2021079339A1 (en) 2021-04-29
TW202128210A (zh) 2021-08-01
JP2023501902A (ja) 2023-01-20
AR120290A1 (es) 2022-02-09

Similar Documents

Publication Publication Date Title
MD3811927T2 (ro) O formă de dozaj parenterală stabilă de acetat de cetrorelix
EA201291417A1 (ru) Устройство для доставки лекарственного средства
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
NZ629004A (en) Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
UY37061A (es) Administracion intradermica de una composicion de inmunoglobulina g
CN204170224U (zh) 一种新型麻醉器
Kovacicova Digital ischaemia following accidental administration: case report
RU2016124629A (ru) Способ индукции суперовуляции у коров-доноров эмбрионов с пролонгированием действия гипофизарных гонадотропинов
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
JP1675942S (ja) 薬剤投与デバイス
JP1678733S (ja) 薬剤投与デバイス
CN204468342U (zh) 畜用疫苗可调连续注射枪
RU2013142835A (ru) Способ лечения ишемического инсульта
JP1676041S (ja) 薬剤投与デバイス
JP1676040S (ja) 薬剤投与デバイス
JP1675945S (ja) 薬剤投与デバイス
JP1675944S (ja) 薬剤投与デバイス
CN204193218U (zh) 新型注射泵延长管
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
CN202715093U (zh) 一种内科用注射针头
RU2013141056A (ru) Способ комплексной терапии преинвазивного и инвазивного рака шейки матки
CO2022002866A2 (es) Formulaciones de insulina y glucagón inyectables por vía subcutánea y métodos de administración
EA027609B9 (ru) Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа
UA118992U (uk) Спосіб гормонального стимулювання самиць дунайського лосося
UA118991U (uk) Спосіб дозування сечовини для проведення швидкого уреазного тесту у хворих на хронічний гелікобактеріоз